Healthcare Industry News: Elekta
News Release - March 10, 2008
Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to Froedtert Hospital in MilwaukeeATLANTA and MILWAUKEE, March 10 (HSMN NewsFeed) -- Elekta Neuromag®, the world-leading equipment for non-invasive measurement of brain activity using Magnetoencephalography (MEG) technology, has been ordered by Froedtert Memorial Lutheran Hospital.
Located in the western suburbs of Milwaukee, Froedtert Hospital has played a critical role in the quality of life in Wisconsin and Northern Illinois since opening its doors in 1980 as a not-for-profit hospital. More than 800 Medical College of Wisconsin physicians and more than 4,000 staff members are dedicated to excellence in patient care, research and medical education at this premier academic medical center.
Froedtert Hospital will receive its new Elekta Neuromag MEG system in the autumn of 2008. With the MEG system from Elekta installed, neurosurgeons, neurologists and those in related fields will be able to non-invasively record human brain activity in real time, better and more accurately than ever before.
MEG technology is regarded as the most efficient method for tracking brain activity at millisecond resolution. Compared to EEG technology, MEG has uniquely accurate localization capabilities. Other technologies, for example Computed Tomography (CT) and Magnetic Resonance Imaging (MRI), provide only anatomical or metabolic information; whereas MEG is a direct measure of neuronal electric activity. When complemented with MRI, MEG increases the ability to understand brain activity and to improve treatment of functional disorders and, in particular, epilepsy.
"We look forward to soon becoming the site of the first whole-head Magnetoencephalography lab in the state," says Elizabeth Ragalie, Director of the Neurosciences Center at Froedtert Hospital. "We intend to use the MEG in our epilepsy program as a powerful new tool for pre-surgical planning. The non-invasive and fast measurement capability of the technology is well suited to the high-quality patient care and advancement of scientific discovery that we strive to achieve here at Froedtert." Ragalie went on to say, "Furthermore, we plan to launch an ambitious research program in conjunction with the Medical College of Wisconsin, which will make use of the unique temporal resolution of MEG technology. We chose the Elekta Neuromag MEG system because its combination of sensitive detectors, robust environmental noise cancellation and versatile software was deemed best able to meet the stringent demands of our users."
"With leading technology to the development of MEG technology and methodology, Elekta was the natural choice when Froedtert made its decision," says Gordon Haid, Director of MEG Sales for North America. "We are pleased to see an increasing interest around the world for Elekta Neuromag systems, particularly in the US."
The Elekta Neuromag 306-channel MEG sensor array has a higher density of detectors than any other system on the market, leading to a more accurate representation of brain activity. The industry's lowest signal-to-noise ratio means that more useful information is acquired, thus yielding the highest information per sample.
The unique design of the sensors combined with advanced software makes it possible to gain data with unsurpassed detail, even from the deepest regions of the brain. The system also has the highest available immunity to magnetic interference, either patient-related or external. Elekta Neuromag also has the lowest operational costs. Elekta Neuromag is technically the most sophisticated MEG/EEG device available on the market today.
Elekta is an international medical technology group, providing oncologists, radiation therapists, neurosurgeons and many other medical specialists with state of the art tools to fight serious disease.
Elekta provides advanced clinical solutions, comprehensive management and information systems as well as services for improved cancer care and management of brain disorders.
Elekta's systems and solutions are used in over 4,500 hospitals around the world. Clinical and information management solutions include, among others, Leksell Gamma Knife® for non-invasive treatment of brain disorders, Elekta Axesse(TM) and Elekta Synergy® for stereotactic and image guided radiation therapy and radiosurgery as well as the MOSAIQ(TM) suite of software for image-enabled EMR and efficient management of clinical and patient data.
With over 2,000 employees globally, the corporate headquarter is located in Stockholm, Sweden and the company is listed on the Nordic Exchange under the ticker EKTAb. More information about Elekta can be found at www.Elekta.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.